medigraphic.com
ISSN 1025-0255 (Electronic)

2012, Number 4

<< Back Next >>

AMC 2012; 16 (4)

Sentinel node biopsy in breast cancer: a case presentation

Saure SVM

Language: Spanish
References: 16
Page: 464-474
PDF size: 198.82 Kb.


ABSTRACT

Introduction: breast cancer is the most frequent neoplasia in the female sex; approximately one million new cases are diagnosed and 400.000 annual deaths in woman worldwide.
Clinical case: the case of a patient with diagnosis and treatment of breast cancer is presented in the University Oncological Hospital María Curie, Camagüey. Cancer has been identified through the sentinel node technique, which is performed for several years in the world as standard in breast cancer treatment. This technique may be done with colorings of methylene blue, isosulfan or by radiopharmaceuticals of nuclear medicine, which leads to avoid the axillary radical dissection and thereby decreases morbidity without changing or influencing in staging, treatment or disease survival.


REFERENCES

  1. Cortés Funes H, Colomer Bosch R. Tratado de oncología. Sección I. En: Cortés Funes H, Colomer Bosch R, editores. Cáncer de mama. 4ta ed. Barcelona: Publicaciones Permanyer; 2009.

  2. Ministerio de Salud Pública. Programa integral para el control del cáncer en Cuba. La Habana: Editorial Ciencias Médicas; 2010.

  3. Veronesi U, Paganelli G, Viale G. Sentinel lymph-node biopsy as a staging procedure in breast cancer: update of a randomised control study. Lancet Oncol. 2006; 7:983-90.

  4. Posther KE, McCall LM, Blumencranz PW. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg. 2005; 242(4):593.

  5. Mansel RE, Fallowfield L, Kissin M. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006; 98(9):599.

  6. Goldhirsch JN, Ingle RD, Gelber AS, Coates B. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 and Panel members. Annals of Oncology. 2009; 20(8): 1319-1329.

  7. Knauer M, Konstantiniuk P, Haid A. Multicentric breast cancer: a new indication for sentinel node biopsy-a multi-institutional validation study. J Clin Oncol. 2006; 24(21):3374.

  8. Shen J, Gilcrease MZ, Babiera GV. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer. 2007; 109(7):1255.

  9. Veronesi U, Paganelli G, Galimberti V. Sentinel lymp node biosy as estaging procedure in breast cancer: update of a randomised controlled study. Lancet oncol. 2006; 7:983-90.

  10. Kirby IB, Chung MA. Breast cancer. En: Kirby IB, editor. Surgical Oncology. New York: Mcgraw-hill; 2005.p.951-3.

  11. Guliano A. Sentinel limphadenectomy in breast cancer. J CLIn Oncol. 1997; 15:2345.

  12. Blessing W, Stolier A, Teng S. A comparison of methylene blue and lymphazurin in breast cancer sentinel node mapping. Am J Surg. 2002; 184:341-5.

  13. Galimberti V. Axillary sentinel lymph node: how low can you go?. Breast. 2009; 18(Suppl 1):S12.

  14. Newman EA, Newman LA. Lymphatic Mapping Techniques and Sentinel Lymph Node Biopsyin Breast Cancer. Surg Clin. 2007; 8(87):353-64.

  15. Katz A, Nimierko A, Gage I. Can axilar dissection be avoided in patients with sentinel lymph node?. J Surg oncol. 2006; 93:550-8.

  16. Mulcahy N. Positive nodes, but axillary dissection not needed. JAMA. 2011; 305:569-75.




2020     |     www.medigraphic.com